Weight gain and ghrelin level after olanzapine monotherapy

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 2, 2011, Pages 632-635

  Chen, Vincent Chin Hung ^a,b   Wang, Tsu Nai ^c   Lu, Mong Liang ^d   Chou, Jen Yu ^e   Ju, Po Chung ^a,b   Wu, Jui Yen ^a   Lin, Zheng Ren ^a,b   Ji, Tsai Tsen ^b   Chou, Chu En ^a   Lee, Chun Te ^a,b   Lai, Te Jen ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Ghrelin; Olanzapine; Weight gain

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GHRELIN; GLUCOSE; OLANZAPINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG RESPONSE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; SCHIZOPHRENIA; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WEIGHT GAIN;

ADIPONECTIN; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; CASE-CONTROL STUDIES; FASTING; FEMALE; GHRELIN; HUMANS; LIPIDS; MALE; TAIWAN; WEIGHT GAIN;

EID: 79952902588     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.01.010     Document Type: Article

References (34)

1. Allison D.B., Mentore J.L., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
2. Ariyasu H., Takaya K., Tagami T., et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001, 86:4753-4758.
3. Baptista T., Kin N.M., Beaulieu S., de Baptista E.A. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002, 35:205-219.
4. Birkenaes A.B., Birkeland K.I., Engh J.A., Faerden A., Jonsdottir H., Ringen P.A., et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008, 28:132-137.
5. Bushe C., Haddad P., Peveler R., Pendlebury J. The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol 2005, 19:28-35.
6. Cummings D.E., Purnell J.Q., Frayo R.S., et al. A pre-prandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001, 50:1714-1719.
7. Hansen T.K., Dall R., Hosoda H., et al. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) 2002, 56:203-206.
8. Horvath T.L., Castaneda T., Tang-Christensen M., Pagotto U., Tschop M.H. Ghrelin as a potential anti-obesity target. Curr Pharm Des 2003, 9:1383-1395.
9. Hosojima H., Togo T., Odawara T., Hasegawa K., Miura S., Kato Y., et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 2006, 20:75-79.
10. Houseknecht K.L., Robertson A.S., Zavadoski W., et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007, 32:289-297.
11. Jin H., Meyer J.M., Mudaliar S., Jeste D.V. Impact of atypical anti-psychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 2008, 100:70-85.
12. Kim B.J., Sohn J.W., Park C.S., et al. Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine. J Korean Med Sci 2008, 23:685-690.
13. Leidy H.J., Gardner J.K., Frye B.R., et al. Circulating ghrelin is sensitive to changes in body weight during a diet and exercise program in normal-weight young women. J Clin Endocrinol Metab 2004, 89:2659-2664.
14. Marder S.R., Essock S.M., Miller A.L., et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004, 161:1334-1349.
15. McGlashan T.H. A selective review of recent North American long-term follow-up studies of schizophrenia. Schizophr Bull 1988, 14:515-542.
16. Mueser K.T., McGurk S.R. Schizophrenia. Lancet 2004, 363:2063-2072.
17. Murashita M., Kusumi I., Inoue T., et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology 2005, 30:106-110.
18. Nakazato M., Murakami N., Date Y., et al. A role for ghrelin in the central regulation of feeding. Nature 2001, 409:194-198.
19. Palik E., Birkas K.D., Faludi G., Karadi I., Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diab Res Clin Pract 2005, 68:S60-S64. Suppl1.
20. Parsons B., Allison D.B., Loebel A., et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009, 110:103-110.
21. Rege S. Anti-psychotic induced weight gain in schizophrenia: mechanisms and management. Aust N Z J Psychiatry 2008, 42:369-381.
22. Rice D.P. The economic impact of schizophrenia. J Clin Psychiatry 1999, 60(Suppl 1):4-6. discussion 28-30.
23. Richards A.A., Hickman I.J., Wang A.Y., Jones A.L., Newell F., Mowry B.J., et al. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol 2006, 26:232-237.
24. Rigamonti A.E., Pincelli A.I., Corra B., et al. Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. J Endocrinol 2002, 175:R1-R5.
25. Ryan M.C., Flanagan S., Kinsella U., Keeling F., Thakore J.H. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004, 74:1999-2008.
26. Sentissi O., Epelbaum J., Olie J.P., Poirier M.F. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 2008, 34:1189-1199.
27. Togo T., Hasegawa K., Miura S., et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacol (Berl) 2004, 172:230-232.
28. Togo T., Kojima K., Shoji M., et al. Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study. Int Clin Psychopharmacol 2004, 19:37-40.
29. Tschop M., Smiley D.L., Heiman M.L. Ghrelin induces adiposity in rodents. Nature 2000, 407:908-913.
30. Tschop M., Weyer C., Tataranni P.A., et al. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001, 50:707-709.
31. Ukkola O., Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities. J Mol Med 2002, 80:696-702.
32. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
33. Wirshing D.A. Schizophrenia and obesity: impact of anti-psychotic medications. J Clin Psychiatry 2004, 65(Suppl 18):13-26.
34. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.